Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Aspirin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 known ✓ | P35354 | 5/20 | 0.67 |
| ▸ | PTGS1 known ✓ | P23219 | 1/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.67 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.67 |
| ▸ | HPGD | P15428 | 4/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.67 |
| ▸ | ESR1 | P03372 | 1/20 | 0.67 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.67 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.67 |
| ▸ | HMGB1 | P09429 | 1/20 | 0.67 |
| ▸ | TSHR | P16473 | 1/20 | 0.67 |
| ▸ | GGT1 | P19440 | 1/20 | 0.67 |
| ▸ | BLM | P54132 | 1/20 | 0.67 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.67 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.67 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.59 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Aspirin SCHEMBL21328428 | 1.00 | KDM4E (0.67) | KDM4EPTGS2HSD17B10HPGDALDH1A1 | |
| Aspirin SCHEMBL191054 | 0.96 | KDM4E (0.67) | KDM4EPTGS2HSD17B10HPGDALDH1A1 | |
| Aspirin SCHEMBL26228 | 0.96 | KDM4E (0.67) | KDM4EPTGS2HSD17B10HPGDALDH1A1 | |
| Aspirin SCHEMBL162391 | 0.96 | KDM4E (0.67) | KDM4EPTGS2HSD17B10HPGDALDH1A1 | |
| Aspirin SCHEMBL1457620 | 0.96 | KDM4E (0.67) | KDM4EPTGS2HSD17B10HPGDALDH1A1 | |
| Aspirin SCHEMBL25284 | 0.96 | KDM4E (0.67) | KDM4EPTGS2HSD17B10HPGDALDH1A1 | |
| Aspirin SCHEMBL3677210 | 0.96 | KDM4E (0.67) | KDM4EPTGS2HSD17B10HPGDALDH1A1 | |
| Aspirin SCHEMBL2157062 | 0.96 | KDM4E (0.67) | KDM4EPTGS2HSD17B10HPGDALDH1A1 | |
| Aspirin SCHEMBL1939134 | 0.96 | KDM4E (0.67) | KDM4EPTGS2HSD17B10HPGDALDH1A1 | |
| Aspirin SCHEMBL7250097 | 0.96 | KDM4E (0.67) | KDM4EPTGS2HSD17B10HPGDALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1318 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115404039-B | Polyurethane adhesive and preparation method and application thereof | 杭州之江有机硅化工有限公司 | 2023-06-16 | — | — | CN | claimed |
| CN-115404039-A | Polyurethane adhesive and preparation method and application thereof | 杭州之江有机硅化工有限公司 | 2022-11-29 | — | — | CN | claimed |
| US-20220008334-A1 | GASTRIC RETENTIVE DEVICES | CLEXIO BIOSCIENCES LTD. (IL) | 2022-01-13 | — | — | US | claimed |
| US-11147766-B2 | Gastric retentive devices | CLEXIO BIOSCIENCES LTD. (IL) | 2021-10-19 | — | — | US | claimed |
| EP-2374478-B1 | NSAID-DISACCHARIDE INCLUSION COMPLEXES FOR ALLEVIATING DAMAGE TO THE GASTROINTESTINAL MUCOSA | NEXT 21 K K (JP) | 2017-08-23 | — | — | EP | claimed |
| US-9649093-B2 | Cavity-filling biopsy site markers | SENORX, INC. (US) | 2017-05-16 | — | — | US | claimed |
| US-9452180-B2 | NSAIDs-induced gastrointestinal mucosal disorder alleviator and manufacturing method thereof | NEXT21 K.K. (JP) | 2016-09-27 | — | — | US | claimed |
| US-20160120510-A1 | CAVITY-FILLING BIOPSY SITE MARKERS | SENORX, INC. | 2016-05-05 | — | — | US | claimed |
| US-20140323429-A1 | NSAIDS-INDUCED GASTROINTESTINAL MUCOSAL DISORDER ALLEVIATOR AND MANUFACTURING METHOD THEREOF | NEXT21 K.K. (JP) | 2014-10-30 | — | — | US | claimed |
| CN-102238964-B | Nsaids-induced gastrointestinal mucosal disorder alleviator and manufacturing method thereof | NEXT21 KK | 2014-08-06 | — | — | CN | claimed |
| US-20040147606-A1 | SYNERGISTIC MIXTURE OF FUDOSTEINE AND ANALGESICS, ANTIPYRETICS | SSP CO., LTD. (JP) | 2004-07-29 | — | — | US | claimed |
| EP-1391201-A1 | MEDICINAL COMPOSITIONS | SSP Co., Ltd. (JP) | 2004-02-25 | — | — | EP | claimed |
| WO-2003089012-A2 | CAVITY FILLING BIOPSY SITE MARKER | SENORX, INC. (US) | 2003-10-30 | — | — | WO | claimed |
| US-20020188196-A1 | Cavity-filling biopsy site markers | SENORX, INC. | 2002-12-12 | — | — | US | claimed |
| CN-1294519-A | Pharmaceutical composition containing a compound having an activity of promoting the absorption of an active ingredient | INPHARMA SA (CH) | 2001-05-09 | — | — | CN | claimed |
| US-5811547-A | Method for inducing crystalline state transition in medicinal substance | NIPPON SHINYAJU CO., LTD. (JP) | 1998-09-22 | — | — | US | claimed |
| US-5128334-A | Side effect reduction, ascorbic acid or derivative | IMMUNO JAPAN INC. (JP) | 1992-07-07 | — | — | US | claimed |
| EP-0437083-A1 | Analgesic and anti-inflammatory medicine | IMMUNO JAPAN INC. (JP) | 1991-07-17 | — | — | EP | claimed |
| US-4229446-A | ANALGESICS, ANTIPYRETICS, ANTIINFLAMMATORY AGENTS | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1980-10-21 | — | — | US | claimed |
| US-3988333-A | Tri-substituted aluminum salts or di-substituted aluminum salts of carboxyl group-containing, pharmaceutically effective compounds | TEIKOKU HORMONE MFG. CO., LTD. (JA) | 1976-10-26 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040147606-A1 | SYNERGISTIC MIXTURE OF FUDOSTEINE AND ANALGESICS, ANTIPYRETICS | PTGES, CCL11, UROD | PTGS2 16/4885PTGS1 26/4885KDM4E 2849/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.